Toralizumab (IDEC-131) 是一种针对CD40L (CD154)的人源化单克隆抗体 (mAb)，由人 γ1 重链和人 kappa 轻链组成。Toralizumab 特异性结合 T 细胞上的人 CD40L，从而阻止 CD40 信号传导。Toralizumab 是一种免疫抑制剂，具有用于活跃的系统性红斑狼疮 (SLE) 研究的潜力。
| 生物活性 | Toralizumab (IDEC-131) is a humanized monoclonal antibody (mAb) againstCD40L (CD154)comprised of human gamma 1 heavy chains and human kappalightchains. Toralizumab binds specifically to human CD40L on T cells, thereby preventingCD40signaling. Toralizumab, a immunosuppressive drug, has the potential for active systemic lupus erythematosus (SLE) research[1][2]. |
| IC50& Target[1][2] | |
| 分子量 | |
| CAS 号 | |
| 中文名称 | |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
